Trials / Completed
CompletedNCT00591214
Safety and PK Study of MP-424 to Treat Chronic Hepatitis C
A Phase I, Open-Label, Single-Dose Study of MP-424 in Patients With Genotype 1b Hepatitis C
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 20 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety, pharmacokinetics and HCV(Hepatitis C virus) RNA (Ribonucleic Acid) kinetics after administration of MP-424 to patients with chronic hepatitis C.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MP-424 (Telaprevir) | Three tablets of MP-424 250mg tablet at a time, every 8 hours, 12 weeks administration (dose in a day: 2250 mg) |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2008-10-01
- Completion
- 2008-10-01
- First posted
- 2008-01-11
- Last updated
- 2026-01-06
- Results posted
- 2012-10-22
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00591214. Inclusion in this directory is not an endorsement.